HR and breast cancer: Firstly, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha (PIK3CA) was approved by international societies for the clinical stratification of BC patients expressing specific receptor profile [hormone receptor (HR)+/HER2-] [1,2].